EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 24,328 | $10,830,826 | +7% | 4.64% |
| 2. | Bourgeon Capital John Zaro | 735 | $327,222 | -47% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $196.34 | 4,243 | $833,070.62 | 73,754 | 2021-08-19 | Filing | |
| $195.14 | 5,757 | $1,123,420.98 | 69,511 | 2021-08-19 | Filing | |
| $197.91 | 15,000 | $2,968,650.00 | 41,210 | 2021-08-02 | Filing | |
| $218.79 | 3,905 | $854,374.95 | 26,210 | 2020-11-10 | Filing | |
| $217.49 | 4,270 | $928,682.30 | 22,305 | 2020-11-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $424.69 | 52 | $22,083.88 | 23,281 | 2025-05-15 | Filing | |
| $505.86 | 400 | $202,344.00 | 4,831 | 2025-05-02 | Filing | |
| $510.00 | 3,231 | $1,647,810.00 | 23,281 | 2025-03-13 | Filing | |
| $500.00 | 3,298 | $1,649,000.00 | 51,671 | 2025-03-10 | Filing | |
| $499.99 | 3,242 | $1,620,967.58 | 51,239 | 2025-03-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 329,391 | $146,644,871 | 0.24% | |
| 2. | 254,347 | $113,235,284 | 0.13% | |
| 3. | 242,754 | $108,074,081 | 0.16% | |
| 4. | 210,089 | $93,531,667 | 0.14% | |
| 5. | 188,004 | $83,699,363 | 0.57% |
News See All
Goldman Sachs Healthcare Stocks: Top 10 Stock Picks
The healthcare sector has been under pressure, underperforming the S&P 500 over the past several years.
Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)?
PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C.
Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Vertex Pharmaceuticals Presents "Unprecedented" Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Billionaire Hedge Funds
